Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: email@example.com. Type 508 Accommodation in the subject line of e-mail.
Influenza Vaccination of Health-Care Personnel
Recommendations of the Healthcare Infection Control Practices
Advisory Committee (HICPAC) and the Advisory Committee on Immunization
Michele L. Pearson, MD1
Carolyn B. Bridges, MD2
Scott A. Harper, MD3
1Division of Healthcare Quality Promotion, National Center for Infectious Diseases
2Epidemiology and Surveillance Division, National Immunization Program
3Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases
The material in this report originated in the National Center for Infectious Diseases, Rima F. Khabbaz, MD, Director; Division of Healthcare
Quality Promotion, Denise M. Cardo, MD, Director; Division of Viral and Rickettsial Diseases, Steve Monroe, PhD, Acting Director; and
National Immunization Program, Anne Schuchat, MD, Director; Epidemiology and Surveillance Division, Alison Mawle, PhD, Acting Director.
Corresponding preparer: Michele L. Pearson, MD, Division of Healthcare Quality Promotion, National Center for Infectious Diseases, 1600
Clifton Road, NE, MS A-31, Atlanta, GA 30333. Telephone: 404-639-4251; Fax: 404-639-4046; E-mail:
This report summarizes recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC)
and the Advisory Committee on Immunization Practices (ACIP) concerning influenza vaccination of health-care personnel
(HCP) in the United States. These recommendations apply to HCP in acute care hospitals, nursing homes, skilled nursing
physician's offices, urgent care centers, and outpatient clinics, and to persons who provide home health care and
emergency medical services. The recommendations are targeted at health-care facility administrators, infection-control professionals,
and occupational health professionals responsible for influenza vaccination programs and influenza infection-control programs
in their institutions. HICPAC and ACIP recommend that all HCP be vaccinated annually against influenza. Facilities
that employ HCP are strongly encouraged to provide vaccine to their staff by using evidence-based approaches that
maximize vaccination rates.
Influenza transmission and outbreaks in hospitals
(1--8) and nursing homes (9--13) are well documented. HCP
can acquire influenza from patients or transmit influenza to
patients and other staff. Despite the documented benefits of
HCP influenza vaccination on patient outcomes
(14,15) and HCP absenteeism (16) and on
reducing influenza infection among staff
(16,17), vaccination coverage among HCP remain
low (i.e., <50%) (18). Because HCP provide care to patients at
high risk for complications of influenza, HCP should be considered a high priority for
expanding influenza vaccine use. In addition, older HCP (i.e., aged
>65 years) and those who have underlying chronic medical conditions or who might
be pregnant are at increased risk for influenza-related complications. Achieving and sustaining high vaccination coverage
among HCP will protect staff and their patients, and reduce disease burden and health-care costs.
This report summarizes recommendations of the Healthcare Infection Control Practices Advisory Committee
(HICPAC) and the Advisory Committee on Immunization Practices (ACIP) concerning influenza vaccination of
health-care personnel (HCP)* in the United States. These recommendations are targeted at health-care facility administrators,
infection control professionals, and occupational health professionals responsible for influenza vaccination programs and
influenza infection control programs in their institutions. HICPAC and ACIP recommend that all HCP be vaccinated annually
against influenza. Facilities that employ HCP are strongly encouraged to provide vaccine to their staff by using
evidence-based approaches that maximize vaccination rates. This report supplements ACIP's previous statement regarding use of
influenza vaccine and antiviral agents (1), which provides details regarding the epidemiology of influenza transmission in
settings, influenza vaccination of nonhealth-care personnel, composition of influenza vaccines, and use of
The summary recommendations contained in this report are categorized by using the HICPAC evidence ranking
system (Table 1). The recommendations were drafted after
review of peer-reviewed scientific articles, and whenever possible are
based on well-designed studies; certain recommendations are based on strong theoretic rationale and expert opinion.
All recommendations have been approved by HICPAC and ACIP. The committees involved in drafting and reviewing
these recommendations included persons with expertise
in infectious diseases, infection control, pediatrics, vaccinology,
internal medicine, and public health.The recommendations are as follows:
Educate HCP regarding the benefits of influenza vaccination and the potential health consequences of influenza illness
for themselves and their patients, the epidemiology and modes of transmission, diagnosis, treatment, and
nonvaccine infection control strategies, in accordance
with their level of responsibility in preventing health-care--associated
influenza (category IB).
Offer influenza vaccine annually to all eligible HCP to protect staff, patients, and family members and to
decrease HCP absenteeism. Use of either available vaccine (inactivated and live, attenuated influenza vaccine [LAIV]) is
recommended for eligible persons. During periods when inactivated vaccine is in short supply, use of LAIV is especially encouraged
when feasible for eligible HCP (category IA).
Provide influenza vaccination to HCP at the work site and at no cost as one component of employee health programs.
Use strategies that have been demonstrated to increase
influenza vaccine acceptance, including vaccination clinics,
mobile carts, vaccination access during all work shifts, and modeling and support by institutional leaders (category IB).
Obtain a signed declination from HCP who decline
influenza vaccination for reasons other than medical
contraindications (category II).
Monitor HCP influenza vaccination coverage and declination at regular intervals during influenza season and
provide feedback of ward-, unit-, and specialty-specific rates to staff and administration (category IB).
Use the level of HCP influenza vaccination coverage as one measure of a patient safety quality program (category II).
Influenza Among HCP
A limited number of prospective and cross-sectional studies provide estimates of incidence of influenza and influenza-like
illness (ILI) among HCP (17,19,20). In one serosurvey of HCP, 23% of HCP had documented serologic evidence of influenza
infection after a mild influenza season; however, of these, 59% could not recall having influenza, and 28% could not recall any
respiratory infection, suggesting a high proportion of asymptomatic illness
(17). In a randomized trial of influenza vaccine among HCP,
13% of placebo recipients subsequently had influenza
infection (18). In a cross-sectional survey of house staff, 37% reported
ILI during an 8-month period (September--April); 9% reported more than one illness. Length of illness varied (range: 1--10
days; mean: 7 days), as did the number of days of work missed (range: 0--10 days; mean:
0.7 days) (20).
Efficacy and Effectiveness of Influenza Vaccines Among Adults
Trivalent inactivated influenza vaccine prevents influenza illness among approximately 70%--90% of healthy adults
aged <65 years when the vaccine and circulating viruses are antigenically similar
(17,21--23). The effectiveness of
inactivated influenza vaccine in preventing influenza illness might be lower when vaccine and circulating viruses are not well matched
or among adults aged >65 years and persons with certain chronic conditions (e.g., diabetes, human immunodeficiency
virus (HIV), or chronic obstructive pulmonary disease)
(24--28). Vaccination of healthy adults also decreases work absenteeism
and use of health-care resources, including antibiotics, when the vaccine and circulating viruses are well matched
(17,21, 23,29--31). In addition, influenza vaccine prevents secondary complications and reduces the risk for
and death among adults aged >65 years with and without high-risk medical conditions (e.g., heart disease and diabetes)
LAIV has demonstrated similar benefits in randomized controlled trials among healthy working adults aged 18--64 years.
In one study, vaccination with LAIV reduced severe febrile illnesses 19% and upper respiratory tract illnesses 24%; LAIV use
also was associated with fewer days of illness and of work lost, fewer health-care provider visits, and reduced use of
prescription antibiotics and over-the-counter medications
(37). These results were recorded during a season in which the vaccine
and circulating influenza A (H3N2) strains were not well matched. In the same study, LAIV vaccination yielded similar
benefits among a subset of healthy adults aged 18--49 years, and antibiotic use in this age group decreased 41%--51%
(37). In one study, overall efficacy of LAIV and inactivated influenza vaccine in preventing laboratory-documented influenza was 85%
and 71%, respectively (38).
Impact of HCP Vaccination on Influenza in Health-Care Settings
Vaccination of HCP is an important component of influenza prevention programs in the United States
(18). Vaccination of HCP reduces transmission of influenza in health-care settings, staff illness and absenteeism, and influenza-related
morbidity and mortality among persons at increased risk for severe influenza illness
(14--17). Use of antiviral drugs used
for chemoprophylaxis or treatment of influenza is an adjunct to (but not a substitute for) vaccination
Transmission of Influenza in Health-Care Settings
Influenza outbreaks in hospitals (4,39) and long-term--care facilities
(40) have been associated with low vaccination
rates among HCP. In addition, higher vaccination levels among staff have been associated with a lower incidence of
nosocomial influenza cases (14,15,39).
In one tertiary care facility in which routine surveillance for influenza was conducted, the relation between staff
vaccination coverage and annual incidence of nosocomial influenza was assessed for 12 influenza seasons during 1987--2000. During
this period, staff vaccination coverage increased from 4% during 1987--1988 to 67% during 1999--2000 (p<0.0001), and
the proportion of laboratory-confirmed cases of influenza that
occurred among HCP decreased from 42% during 1990--1993
to 9% during 1997--2000 (p<0.0001). The proportion of nosocomial cases among hospitalized patients
decreased 32% to 0 (p<0.0001). After controlling for potential confounders by using logistic regression, a significant and
inverse relationship was demonstrated between vaccination rates among HCP and the rate of nosocomial influenza among
patients, suggesting that staff vaccination contributed to the
observed decline in the number of nosocomial influenza cases
Staff Illness and Absenteeism
During an influenza season, HCP might acquire influenza from infected patients with resulting morbidity and
absenteeism. The impact of influenza vaccination on staff illness and absenteeism has been evaluated in two randomized,
placebo-controlled, double-blind trials. In one trial, HCP who received vaccine had 28% fewer documented lost work
days attributable to respiratory infections (1.0 and 1.4, respectively;
p = 0.02) and 28% fewer days on which they felt unable
to work, whether they were on or off duty (2.5 and 3.5, respectively;
p = 0.02). Vaccination did not reduce either the number
of episodes (1.8 and 2.0, respectively) or the total number of days (13.5 and 14.6, respectively) of respiratory infection
(16). In a second trial conducted in two large teaching hospitals for 3 consecutive years that measured serologically confirmed
influenza, days of febrile respiratory illness, and days absent from work, HCP who received influenza vaccine had a substantially
lower incidence of influenza than controls (1.7% and 13.4%, respectively) with an estimated vaccine efficacy against
serologically defined influenza A and influenza B infection
of 88% and 89%, respectively. HCP who received influenza
vaccine also tended to have fewer total respiratory illnesses (28.7 and 40.6 per 100 persons, respectively; p = 0.57) and days of lost work (9.9
and 21.1 per 100 persons, respectively; p = 0.41) than did controls
In a cross-sectional survey, similar reductions in staff illness episodes and days of illness were reported
(20). Overall, compared with unvaccinated coworkers, vaccinated house staff reported 23% fewer ILIs (42 and 54 per 100
persons, respectively; p = 0.03), 27% fewer days of illness (80 and 115 per 100 persons, respectively; p = 0.02), and a 59% reduction
in illness during vacation time (1.7% and 4.0% of persons,
respectively; p = 0.08). The two groups had a similar number of
work days attributable to ILI (18 and 21 per 100 subjects, respectively; p = 0.69). During influenza season, vaccination
was associated with reductions of 30% in ILI (p = 0.05), 43% in the proportion of house staff reporting illnesses associated
with fever and cough (p = 0.05), and 63% in illnesses associated with fever and cough (p = 0.03). The inability to
consistently demonstrate statistically significant decreases in absenteeism among staff who received vaccination is likely attributable to
the finding that HCP tend to work despite illness
HCP who are clinically or subclinically infected can transmit influenza virus to other persons. Decreasing transmission
of influenza from caregivers to persons at high risk might
reduce influenza-related deaths among persons at high risk
for complications from influenza.
Residents of long-term--care facilities are particularly vulnerable to influenza and influenza-related complications.
In1999, an estimated 1.6 million persons resided in nursing homes in the United States
(42). During influenza outbreaks in
long-term--care facilities, attack rates among residents have ranged as high as 25%--60%, with case-fatality rates of 10%--20%
(13,43--45). When vaccine and epidemic strains are well matched, achieving increased vaccination rates among persons living in
closed settings (e.g., nursing homes and other chronic-care facilities) and among staff can reduce the risk for outbreaks by
inducing herd immunity (32).
Two randomized controlled trials have evaluated the
impact of influenza vaccination of HCP on the outcomes of
residents in nursing homes. In one study, staff vaccination was associated with a 43% decrease in incidence of ILI (odds ratio [OR]
= 0.6; 95% confidence interval [CI] = 0.3--0.9) and a 44% decrease in overall mortality among facility residents, from 17%
to 10% (OR = 0.6; 95% CI = 0.4--0.8) (15). No virologic data were provided in this study. In a second study, 20
long-term--care facilities were randomized to have vaccine routinely offered (intervention facilities) or not offered (control facilities)
to their staff (14). Facilities were paired by number of beds and patient vaccination policies. Staff vaccination coverage was
higher in intervention facilities than in control facilities (50.9% and 4.9%, respectively). Crude mortality rates were 42%
lower among residents in facilities with higher staff vaccination coverage than those in control facilities (13.6% and
22.4%, respectively; OR = 0.6; 95% CI = 0.4--0.8; p = 0.014). Incidence of laboratory-confirmed influenza did not differ between
the two groups (5.4% and 6.7%, respectively), but postmortem samples from patients in control facilities were more likely to
be positive for influenza by a polymerase chain reaction test than samples from patients in intervention facilities (six [20%] of
30 and none of 17, respectively; p = 0.055), suggesting that in this study population, HCP vaccination reduced
influenza-related mortality in patients despite not reducing the incidence of non-fatal influenza infection. In neither study was a
significant association demonstrated between patient vaccination and mortality. Randomized trials assessing the impact of
staff vaccination on patient outcomes in acute care facilities have not been conducted, but low staff vaccination coverage has
been correlated with influenza outbreaks in hospitals
Cost-Effectiveness of Influenza Vaccine
Cost-effectiveness studies of adults aged <65 years indicate that vaccination can reduce both direct medical costs
and indirect costs from work absenteeism
(21,23,29,30,46,47), resulting in 13%--44% fewer health-care provider visits,
18%--45% fewer lost workdays, 18%--28% fewer days working with reduced effectiveness, and a 25% decrease in antibiotic use
for ILI (21,29,48,49). Among healthy persons aged 18--64 years, vaccination can save an estimated $60--$4,000 per
illness, depending on the cost of vaccination, the influenza
attack rate, and vaccine effectiveness against ILI
(23). In another economic analysis, vaccination resulted in an average annual cost savings of $13.66 per person vaccinated
(50); however, other analyses have not demonstrated cost savings
(21). Among studies of healthy young adults, >70% of the costs prevented were
associated with reductions in lost work productivity.
Vaccination Coverage Levels Among HCP
During 1989--2003, HCP vaccination coverage levels in the United States increased substantially, from 10% to
40%; however, coverage levels have remained relatively constant since 1997
(18). One of the national health objectives for 2010 is
to achieve HCP vaccination coverage levels of 60% (objective no. 14-29g)
(51). Substantially lower vaccination rates have
reported among HCP who have contact with certain populations at high risk
(12,52--54). In addition, HCP vaccination coverage varies by level and years of training, age, occupational group, and facility type
Barriers to HCP Vaccination
Reported barriers to HCP receipt or acceptance of influenza vaccination include fear of vaccine side effects (particularly
ILI symptoms) (20,55,57--61), insufficient time or inconvenience
(20), perceived ineffectiveness of the vaccine
(20,55,58,59), medical contraindication
(55), perceived low likelihood of contracting influenza
(55,60,62), reliance on treatment with homeopathic medications
(55,62), avoidance of medications
(57), and fear of needles (57,59). Factors
facilitating vaccine acceptance include a desire for
self-protection (20,58,61), previous receipt of influenza vaccine
(57,58,63--65), a desire to protect patients
(61), and perceived effectiveness of vaccine
Strategies for Improving HCP Vaccination Rates
Facilities that employ HCP are strongly encouraged to provide vaccine to staff by using evidence-based approaches
that maximize vaccination rates. Successful HCP vaccination programs are multifaceted and combine publicity and education
to combat fears and misconceptions about influenza and
influenza vaccines, use of reminder recall systems, efforts to
remove administrative and financial barriers, role modeling, and monitoring and feedback on vaccination coverage
(66). In contrast, single-component interventions will likely have minimal effectiveness in achieving desired vaccination coverage levels
Education and Campaigns
HCP knowledge, perceptions, and attitudes regarding
influenza and influenza vaccination vary
(20). Basic knowledge about influenza and influenza vaccination has been associated with vaccine receipt
(57,68,69), and participation in structured
in-service education or conferences has been associated
with improved vaccination rates (62,65). Educational programs
should emphasize the benefits of HCP vaccination for staff and patients
(70). Organized campaigns that promote and make
vaccine accessible can improve vaccination rates among HCP
Vaccination of senior medical staff or opinion leaders has been associated with higher vaccination acceptance among
staff members under their leadership
(55,69,72,73). For example, medical students who have contact with infectious
disease specialists are more likely to be vaccinated
Removing administrative barriers (e.g., costs)
(71) and providing vaccine in locations and at times easily accessible by
HCP can substantially improve vaccine acceptance
(40,52,55,72,74,75). In one survey, 33% of HCP reported that they
would reject vaccination if they were required to pay for the vaccine
Making vaccine readily accessible at congregate areas (e.g., clinics), during conferences, or by use of mobile carts
(40,52,55,72) has been demonstrated to improve vaccination coverage rates. Use of mobile carts has been associated with increased
vaccine acceptance during outbreaks and nonoutbreak situations
(75,76) . In a 3-year prospective study in a
630-bed acute care hospital, a sustained four- to fivefold
increase in vaccination rates was associated with using mobile carts to deliver vaccine to staff
rather than requiring HCP to visit an employee health center to receive vaccine. Provision of modest incentives also has been
associated with improved vaccine acceptance among HCP
(77). However, the benefits of vaccine deputies or peer-vaccinators have not
been consistently associated with improved HCP vaccination
Measurement and Feedback
HCP influenza vaccination coverage should be regularly measured and reported. Posting of vaccination coverage levels
in different areas of the hospital is a component of successful vaccination programs
(6). Monitoring vaccination coverage by
facility area (e.g., ward or unit) or occupational group allows facilities to identify where vaccination levels are low
and interventions should be targeted. In addition, HICPAC has recommended that HCP influenza vaccination coverage be used
as a health-care quality measure in those states that mandate public reporting of health-care--associated infections
The independent contribution of signed declination statements to improving HCP vaccination has not been
studied. However, obtaining declination statements from HCP who refuse vaccination for reasons other than medical
contraindications can assist facilities in identifying personnel who might require targeted education or other interventions to overcome
barriers to vaccine acceptance. In addition, collection of such information will allow health-care facilities to determine
what proportion of their staff are reached and offered
Legislation and Regulation
Legislative and regulatory efforts have favorably affected hepatitis B vaccination rates among HCP
(79,80). As of January 2005, a total of 13 states (Alabama, Arkansas, Kentucky, Maine, Maryland, New Hampshire, New York, Oklahoma,
Oregon, Pennsylvania, Rhode Island, Texas, and Utah) and the District of
Columbiawere reported to have enacted
regulations regarding influenza vaccination of staff in long-term--care facilities
(67,81). However, because only one state
(Pennsylvania) has monitored the impact of its laws on nursing home staff vaccination rates, data are insufficient to assess the overall
impact of these legislative efforts on HCP influenza vaccination coverage (CDC, unpublished data, 2005).
Recommendations for Using Inactivated Influenza Vaccine and LAIV
All HCP should be vaccinated annually against influenza. Either inactivated influenza vaccine or LAIV can be used to
reduce the risk for influenza among HCP (Table 2). LAIV is approved for use only among nonpregnant healthy persons aged
5--49 years. HCP who work with severely immunocompromised patients who require a protected environment should
not receive LAIV. Inactivated influenza vaccine is approved for all persons aged >6 months who lack vaccine
contraindications, including those with high-risk conditions (see Recommendations for Prioritization of Influenza Vaccine During the
2005--06 Influenza Season). Four influenza vaccines have been approved for use in the United States during the 2005--06 season
Inactivated Influenza Vaccine Recommendations
Dosage and Route
Because immunity declines during the year after vaccination, HCP eligible to receive inactivated influenza vaccine should
be administered 1 dose of the current year's vaccine each year
(82,83). The intramuscular route is recommended for
inactivated influenza vaccine. Adults should be vaccinated in the deltoid muscle, ideally by using a needle of length
>1 inch because needles of length <1 inch might not penetrate muscle tissue in certain adults
Persons Who Should Not Be Vaccinated with Inactivated
Inactivated influenza vaccine should not be administered to persons known to have anaphylactic hypersensitivity to eggs
or to other components of the influenza vaccine without first consulting a physician (see Side Effects and Adverse
Reactions Associated with Vaccination). Prophylactic use of antiviral agents is an option for preventing influenza among such
persons. However, persons who have a history of anaphylactic hypersensitivity to vaccine components but who are also at high risk
for complications from influenza can benefit from vaccine after appropriate allergy evaluation and desensitization
(18). Information regarding vaccine components is
located in package inserts from each manufacturer. Persons with acute
febrile illness typically should not be vaccinated until their symptoms have abated. However, minor illnesses with or without fever
do not contraindicate use of influenza vaccine.
LAIV licensed for use in the United States
(FluMist manufactured by MedImmune, Inc., Gaithersburg,
Maryland [http//www.medimmune.com]) is a live, trivalent, intranasally administered vaccine that is
attenuated, producing mild or no signs or symptoms
related to influenza virus infection;
temperature-sensitive, a property that limits the replication of the vaccine viruses at 100.4°--102.2° F
(38°C--39° C) and thus restricts LAIV viruses from replicating efficiently in human lower airways; and
cold-adapted, replicating efficiently at 77° F (25° C), a temperature that is permissive for replication of LAIV viruses
but restrictive for replication of different wild-type viruses.
The immunogenicity of the approved LAIV has been
assessed in multiple studies (85--91). LAIV virus strains
replicate primarily in nasopharyngeal epithelial cells. The protective mechanisms induced by vaccination with LAIV are not
completely understood but appear to involve both serum and nasal secretory antibodies. No single laboratory measurement
closely correlates with protective immunity induced by LAIV.
Shedding and Transmission of Vaccine Viruses
One concern regarding use of LAIV among HCP has been the potential for transmitting vaccine virus from
persons receiving vaccine to nonimmune patients at high risk. Available data indicate that children and adults vaccinated with
LAIV can shed vaccine viruses for >2 days after vaccination, although in lower titers than typically occur with shedding of
wild-type influenza viruses. Shedding should not be equated with person-to-person transmission of vaccine
viruses, although transmission of shed vaccine viruses from vaccinated persons to nonvaccinated persons has been documented in
rare instances among children in a day care center
In one study of 20 healthy vaccinated adults aged 18--49 years, the majority of vaccine virus shedding occurred within
the first 3 days after vaccination, although in one vaccinated person, viral shedding was detected on day 7 after vaccination
(93). No vaccine viruses were shed >10 days after vaccination, and duration or type of symptoms associated with
receipt of LAIV did not correlate with duration of shedding of vaccine viruses
(93). In another study of 14 healthy adults aged
18--49 years, 50% of vaccinated persons had viral antigen detected by direct immunofluorescence or rapid antigen tests within
7 days of vaccination; the majority of viral shedding was
detected on day 2 or 3 (94). Person-to-person transmission of vaccine
viruses was not assessed in either of these studies.
One study conducted in a child care center assessed transmissibility of vaccine viruses from 98 vaccinated persons to
99 unvaccinated controls aged 8--36 months; 80% of vaccine recipients shed one or more virus strains (mean duration: 7.6
days). One influenza type B isolate was recovered from a placebo recipient and confirmed to be vaccine-type virus; the
isolate retained the cold-adapted, temperature-sensitive,
attenuated phenotype and possessed the same genetic
sequence as a virus shed from a vaccine recipient in the same children's play group. The placebo recipient from whom the influenza type B
vaccine virus was isolated exhibited symptoms that were
similar to those experienced by vaccine recipients. The estimated probability
of acquiring vaccine virus after close contact with a single LAIV recipient in this child care population was
Using LAIV for HCP
LAIV may be used for vaccination of healthy, nonpregnant persons aged 5--49 years, including HCP. When feasible, use
of LAIV for vaccination of eligible HCP is especially encouraged during periods of limited supply of inactivated
influenza vaccine because use of LAIV for HCP might increase availability of inactivated influenza vaccine for persons at high risk.
Use of LAIV also provides an alternative vaccine strategy for HCP who avoid influenza vaccination because of an aversion
to intramuscular injections.
Persons Who Should Not Receive LAIV
The following populations should not receive LAIV:
persons aged <5 years or >50 years;
persons with asthma, reactive airways disease or other chronic disorders of the pulmonary or cardiovascular systems;
persons with other underlying medical conditions, including metabolic diseases such as diabetes, renal dysfunction,
and hemoglobinopathies; or persons with known or suspected immunodeficiency diseases or who
are receiving immunosuppressive therapies;
children or adolescents receiving aspirin or other salicylates (because of the association of Reye syndrome with
wild-type influenza infection);
persons with a history of Guillain-Barré syndrome (GBS);
persons who have close contact with severely immunosuppressed persons (e.g., patients with hematopoietic stem
cell transplants) during those periods in which the
immunosuppressed person requires care in a protective environment; or
persons with a history of hypersensitivity, including anaphylaxis, to any of the components of LAIV or to eggs.
LAIV Dosage and Administration
Eligible HCP should receive 1 dose of LAIV. LAIV is
intended only for intranasal administration and should not
be administered by the intramuscular, intradermal, or intravenous route. Administration can be accomplished by holding
an individual sprayer in the palm of the hand until thawed, with subsequent immediate administration.
Alternatively, the vaccine can be thawed in a refrigerator and stored at 35.6° F--46.4° F (2° C--8° C) for
<60 hours before use. Vaccine should not be refrozen after thawing. LAIV is supplied in a prefilled single-use sprayer containing 0.5 mL of
vaccine. Approximately 0.25 mL is sprayed into the first nostril while the recipient is in the upright position. An attached
dose-divider clip is removed from the sprayer to administer the second half of the dose into the other nostril. If the vaccine
recipient sneezes after administration, the dose should not be repeated.
LAIV may be administered to persons with minor acute illnesses (e.g., diarrhea or mild upper respiratory tract
infection, with or without fever). However, if clinical judgment indicates the presence of nasal congestion that might impede delivery
of vaccine to the nasopharyngeal mucosa, deferral of administration should be considered until resolution of the illness.
Whether concurrent administration of LAIV with other vaccines affects the safety or efficacy of either LAIV or
the simultaneously administered vaccine is unknown. In the
absence of specific data indicating interference, adherence to
ACIP's general recommendations for vaccination is prudent
(95). Inactivated vaccines do not interfere with the immune response
to other inactivated vaccines or to live vaccines. An inactivated vaccine can be administered either simultaneously or at any
time before or after LAIV. Whenever possible, two live vaccines not administered on the same day should be
administered >4 weeks apart.
Recommended Vaccines for HCP Who Have Close Contact with
Severely Immunosuppressed Persons
Inactivated influenza vaccine is the preferred vaccine for use among HCP who have close contact with
severely immunosuppressed persons (e.g., patients with hematopoietic stem cell transplants) during those periods in which
the immunosuppressed person requires care in a protective environment. The rationale for not using LAIV among HCP caring
for such patients is the theoretic risk that a live, attenuated vaccine virus could be transmitted to the severely
immunosuppressed person. HCP who receive LAIV should refrain from contact with severely immunosuppressed patients for 7 days after
vaccine receipt. In addition, visitors who have received LAIV should refrain from contact with severely immunosuppressed persons
for 7 days after vaccination; however, such persons need not be excluded from visitation of patients who are not
severely immunosuppressed. Either inactivated influenza vaccine or LAIV can be used to vaccinate HCP who have close contact
with persons with lesser degrees of immunosuppression (e.g., persons with diabetes, persons with asthma taking corticosteroids,
or persons infected with human immunodeficiency virus) or who are in close contact with all other persons at high risk.
Personnel Who May Administer LAIV
The risk of acquiring vaccine viruses from the environment is unknown but likely small. Nevertheless,
severely immunosuppressed persons should not administer LAIV because
introduction of low levels of vaccine virus into
the environment probably cannot be avoided when administering LAIV. However, other persons with conditions placing them
at high risk for influenza complications (e.g., pregnant women, persons with asthma, and persons aged >50 years)
may administer LAIV.
LAIV and Use of Influenza Antiviral Medications
How LAIV coadministration with influenza antiviral medications affects safety and efficacy has not been studied.
However, because influenza antivirals reduce replication of influenza viruses, LAIV should not be administered until 48 hours
after cessation of influenza antiviral therapy, and influenza antiviral medications should not be administered for 2 weeks
after receipt of LAIV.
LAIV must be stored at -59° F (-15° C) or colder. LAIV may be stored in frost-free freezers without using a freezer-box.
LAIV can be thawed in a refrigerator and stored at
35.6° F--46.4° F (2º
C--8º C) for <60 hours before use. It should not be
refrozen after thawing. Additional information regarding LAIV storage is available at
Vaccination of Specific HCP Populations
Pregnant women are at increased risk for influenza-related complications
(96--103) and hospitalizations (104). Therefore,
all HCP who are pregnant during the influenza season should be vaccinated against influenza. However, pregnant women
should receive only inactivated influenza vaccine; LAIV is not recommended for use during pregnancy. Inactivated influenza
vaccine may be administered in any trimester. One study of influenza vaccination of approximately 2,000 pregnant
women demonstrated no adverse fetal effects associated with receipt of inactivated influenza vaccine
Influenza vaccine does not affect the safety of mothers who are breastfeeding or their infants. Breastfeeding does
not adversely affect the immune response and is not a contraindication for vaccination.
Persons Infected with HIV
Detailed information on the use of influenza vaccine among persons infected with HIV has been published previously
(18). Because influenza can result in serious illness and influenza vaccination can result in the production of protective
antibody titers, vaccination with inactivated vaccine will benefit HIV-infected persons, including those that are pregnant.
Timing of Annual Influenza Vaccination of HCP
Timing of Organized Vaccination Campaigns
Planning for influenza campaigns should begin as early as February or March
(106). The optimal time to vaccinate HCP is during October--November. Beginning in October each year, health-care facilities should offer influenza vaccinations to
all full- and part-time staff. Particular emphasis should be placed on vaccinating HCP who care for persons at high
risk. Vaccination programs should educate HCP regarding the benefits of vaccination and the potential health consequences
of influenza illness for themselves and their patients. As part of
employee health programs, all HCP should be
provided convenient access to free influenza vaccine at the work site
Vaccination in December and Later
To improve vaccine coverage among HCP, influenza vaccine should continue to be offered in December and throughout
the influenza season as long as vaccine supplies are available, even after influenza activity has been documented in the
community. In the United States, seasonal influenza activity can increase as early as October or November, but influenza activity has
not reached peak levels in the majority of recent seasons until late December--early March. Therefore, although the timing
of influenza activity can vary by region, vaccine administered after November is likely to be beneficial in the majority of
influenza seasons. Adults achieve peak antibody protection against influenza infection 2 weeks after vaccination
Recommendations for Prioritization of Influenza Vaccination During
the 2005--06 Influenza Season
As a result of influenza vaccine distribution delays or
supply shortages in the United States during recent influenza
seasons (110,111), in September 2005, CDC issued recommendations for prioritizing the use of inactivated vaccine during the
2005--06 influenza season to ensure that early vaccine is available for those at the highest risk for complications from influenza
(112). On the basis of uncertainties in doses and distribution, CDC recommended that the following groups receive priority
for inactivated influenza vaccine until October 24, 2005:
persons aged >65 years with and without comorbid
residents of long-term--care facilities,
persons aged 2--64 years with comorbid conditions,
children aged 6--23 months,
HCP who provide direct patient care, and
household contacts and out-of-home caregivers of children aged <6 months
These groups correspond to tiers 1A--1C in the table of
inactivated influenza vaccine priority groups in the event
of vaccination supply disruption that was published previously
(113). After October 24, 2005, all persons were eligible
Tiered use of prioritization was not recommended for LAIV administration. LAIV may be administered at any time
for vaccination of nonpregnant healthy persons aged 5--49 years, including the majority of HCP, other persons in close
contact with persons at high risk for influenza-related complications, and others desiring protection against influenza
Side Effects and Adverse Reactions Associated with Vaccination
Inactivated Influenza Vaccine
When educating HCP regarding potential side effects, providers should emphasize that 1) inactivated influenza
vaccine contains noninfectious killed viruses and cannot cause influenza; and 2) coincidental respiratory disease unrelated
to influenza vaccination can occur after vaccination. The occurrence of vaccine-related side effects has had limited to
no impact on rates of absenteeism among HCP
The most frequent side effect of vaccination (affecting 10%--64% of patients) is soreness at the vaccination site,
typically lasting <2 days (21,114--116). Local reactions typically are mild and rarely interfere with a person's ability to conduct
everyday activities. In a controlled trial, only body aches (25.1%) were reported more frequently after inactivated
influenza vaccine than placebo-injection (20.8%)
Fever, malaise, myalgia, and other systemic symptoms can occur after vaccination with inactivated vaccine and
most often affect persons (e.g., infants) with no previous exposure to the influenza virus antigens in the vaccine
(118,119). Such reactions typically begin 6--12 hours after vaccination and can persist for 1--2 days. Recent placebo-controlled trials demonstrate that
among older persons and healthy young adults, administration of split-virus
(i.e., detergent-disrupted virion) influenza vaccine is
not associated with higher rates of systemic symptoms (e.g., fever, malaise, myalgia, and headache) compared with placebo
injections (21,114--116). No increase in asthma exacerbations has been documented in association with receipt of influenza vaccine
Severe Adverse Events
Immediate and presumably allergic reactions (e.g., hives, angioedema, allergic asthma, and systemic anaphylaxis)
rarely occur after influenza vaccination
(120). These reactions probably result from hypersensitivity to certain vaccine
components; the majority of reactions probably are caused by residual egg protein. Although current influenza vaccines contain only
a limited quantity of egg protein, this protein can induce
immediate hypersensitivity reactions among persons who have
severe egg allergy. Persons who have had hives or swelling of the lips or tongue, or who have experienced acute respiratory distress
or collapse after eating eggs should consult a physician for appropriate evaluation to help determine if vaccine should
be administered. Persons who have documented immunoglobulin
E (IgE)-mediated hypersensitivity to eggs, including those
who have had occupational asthma or other allergic responses to egg protein, might also be at increased risk for allergic reactions
to influenza vaccine, and consultation with a physician should be considered. Protocols have been published for
administering influenza vaccine safely to persons with egg allergies
Hypersensitivity reactions to any vaccine component can
occur. Although exposure to vaccines containing thimerosal can
lead to induction of hypersensitivity, the majority of
patients do not have reactions to thimerosal when it is administered as
a component of vaccines, even when patch or intradermal tests for thimerosal allergy indicate hypersensitivity
(124,125). When reported, hypersensitivity to thimerosal
typically has consisted of local, delayed hypersensitivity reactions
Investigations to date indicate no substantial increase in GBS associated with influenza vaccines (other than the 1976
swine influenza vaccine) (126--130). If current influenza vaccines pose a risk for GBS, the estimated risk is approximately
one additional case per million persons vaccinated, with the total combined number of GBS cases peaking 2 weeks
after vaccination (131). This estimated risk for GBS is substantially less than the risk for severe influenza, which can be
prevented by vaccination among all age groups, especially persons aged
>65 years and those who have medical indications for
influenza vaccination. The potential benefits of influenza vaccination in preventing serious illness, hospitalization, and
death substantially outweigh the possible risks for experiencing
vaccine-associated GBS. The average case-fatality ratio for GBS is
6% and increases with age (132,133). No evidence indicates that the case-fatality ratio for GBS differs among vaccinated
persons and those not vaccinated.
Incidence of GBS among the general population is low, but persons with a history of GBS have a substantially
greater likelihood of subsequently experiencing GBS than persons without such a history
(128,134). Whether influenza vaccination might increase the risk for recurrence of GBS is unknown; for this reason, persons who are not at high risk for severe
influenza complications and who are known to have experienced GBS within 6 weeks after a previous influenza vaccination should
not receive vaccine. Chemoprophylaxis using influenza antivirals might be an alternative for such persons.
Although data are limited, for the majority of persons who have a history of GBS and who are at high risk for severe complications
from influenza, the established benefits of influenza
vaccination justify yearly vaccination. Health-care professionals
should promptly report all clinically significant adverse events after influenza vaccination to the Vaccine
Adverse Event Reporting System (VAERS), even if evidence is lacking that the vaccine caused the event.
Until additional data are available, persons at high risk for experiencing complications from influenza infection
(e.g., immunocompromised patients; patients with asthma, cystic fibrosis, or chronic obstructive pulmonary disease; or
persons aged >65 years) should not be vaccinated with LAIV. Protection from influenza among these groups should be
accomplished by using inactivated influenza vaccine.
Among adults, runny nose or nasal congestion (28%--78%), headache (16%--44%), and sore throat (15%--27%) have
been reported more often among vaccine recipients than placebo recipients
(37,135,136). In one clinical trial among a subset
of healthy adults aged 18--49 years, signs and symptoms
reported more frequently among LAIV recipients (n = 2,548)
than placebo recipients (n = 1,290) within 7 days after each dose included cough (13.9% and 10.8%, respectively); runny
nose (44.5% and 27.1%, respectively); sore throat (27.8% and 17.1%, respectively); chills (8.6% and 6.0%, respectively);
and tiredness or weakness (25.7% and 21.6%, respectively)
(37). Pneumonia, bronchitis, bronchiolitis, or central nervous
system events have not been observed more frequently among LAIV than among placebo recipients.
Severe Adverse Events
Serious adverse events associated with receipt of LAIV among healthy adults aged 18--49 years occur at a rate of <1%
(137). However, surveillance should continue for adverse events that might not have been detected in previous studies.
Health-care professionals should promptly report to VAERS all clinically significant adverse events after LAIV administration, even
if evidence is lacking that the vaccine caused the event.
Additional Information Regarding Influenza Infection Control in
Additional information on controlling and preventing
influenza in health-care settings is available in the
Bradley SF. The Long-Term--Care Committee of the Society for Healthcare Epidemiology of America. Prevention
of influenza in long-term care facilities. Infect Control Hosp Epidemiol 1999;20:629--37.
Sneller V-P, Izurieta H, Bridges C, et al. Prevention and control of vaccine-preventable diseases in long-term care
facilities. Journal of the American Medical Directors Association 2000;1(Suppl):S2--37.
Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in healthcare settings. Clin
Infect Dis 2003;37:1094--101.
Talbot TR, Bradley SE, Cosgrove SE, Ruef C, Siegel JD, Weber DJ. Influenza vaccination of healthcare workers and
vaccine allocation for healthcare workers during vaccine shortages. Infect Control Hosp Epidemiol 2005; 26:882--90.
Malavaud S, Malavaud B, Sandres K, et al. Nosocomial outbreak of influenza virus A (H3N2) infection in a solid organ transplant
department. Transplantation 2001;72:535--7.
Maltezou HC, Drancourt M. Nosocomial influenza in children. J Hosp Infect 2003;55:83--91.
Weinstock DM, Eagan J, Malak SA, et al. Control of influenza A on a bone marrow transplant unit. Infect Control Hosp Epidemiol 2000;
Cunney RJ, Bialachowski A, Thornley D, Smaill FM, Pennie RA. An outbreak of influenza A in a neonatal intensive care unit. Infect Control
Hosp Epidemiol 2000;21:449--54.
Hall CB, Douglas RG Jr. Nosocomial influenza infection as a cause of intercurrent fevers in infants. Pediatrics 1975;55:673--7.
Salgado CD, Farr BM, Hall KK, Hayden FG. Influenza in the acute hospital setting. Lancet Infect Dis 2002;2:145--55.
Kapila R, Lintz DI, Tecson FT, Ziskin L, Louria DB. A nosocomial outbreak of influenza A. Chest 1977;71:576--9.
Sartor C, Zandotti C, Romain F, et al. Disruption of services in an internal medicine unit due to a nosocomial influenza outbreak. Infect
Control Hosp Epidemiol 2002;23:615--9.
Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home
outbreaks of influenza A (H3/N2). Am J Epidemiol 1991;134: 988--97.
Drinka PJ, Krause P, Schilling M, Miller BA, Shult PA, Gravenstein S. Report of an outbreak: nursing home architecture and influenza-A
attack rates. J Am Geriatr Soc 1996;44:910--3.
Degelau J, Somani SK, Cooper SL, Guay DRP, Crossley KB. Amantadine-resistant influenza in a nursing facility. Arch Intern Med
Coles FB, Balzano GJ, Morse DL. An outbreak of influenza A (H3N2) in a well immunized nursing home population. J Am Geriatr
Morens DM, Rash VM. Lessons from a nursing home outbreak of influenza A. Infect Control Hosp Epidemiol 1995;16:275--80.
Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care:
a randomised controlled trial. Lancet 2000;355(9198): 93--7.
Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of
elderly patients. J Infect Dis 1997;175:1--6.
Saxen H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health
care workers. Pediatr Infect Dis J 1999;18:779--83.
Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals:
a randomized trial. JAMA 1999;281:908--13.
Elder AG, O'Donnell B, McCruden EA, Symington IS, Carman WF. Incidence and recall of influenza in a cohort of Glasgow healthcare
workers during the 1993-4 epidemic: results of serum testing and questionnaire. BMJ 1996;313(7067):1241--2.
Lester RT, McGeer A, Tomlinson G, Detsky AS. Use of, effectiveness of, and attitudes regarding influenza vaccine among house staff.
Infect Control Hosp Epidemiol 2003;24:839--44.
Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a
randomized controlled trial. JAMA 2000;284:1655--63.
Palache AM. Influenza vaccines. A reappraisal of their use. Drugs 1997;54:841--56.
Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 2000;18:957--1030.
Blumberg EA, Albano C, Pruett T, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect
Dorrell L, Hassan I, Marshall S, Chakraverty P, Ong E. Clinical and serological responses to an inactivated influenza vaccine in adults with
HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers. Int J STD AIDS 1997;8:776--9.
Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals.
A randomized double-blind placebo-controlled trial. JAMA 1994;272:1661--5.
McElhaney JE, Beattie BL, Devine R, Grynoch R, Toth EL, Bleackley RC. Age-related decline in interleukin 2 production in response to
influenza vaccine. J Am Geriatr Soc 1990;38:652--8.
Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med
Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med
Smith JW, Pollard R. Vaccination against influenza: a five-year study in the Post Office. J Hyg (Lond) 1979;83:157--70.
Patriarca PA, Weber JA, Parker RA, et al. Risk factors for outbreaks of influenza in nursing homes. A case-control study. Am J
Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review
of the literature. Ann Intern Med 1995;123:518--27.
Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health
maintenance organization. Ann Intern Med 1994;121:947--52.
Nordin J, Mullooly J, Poblete S, et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older
in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis 2001;184:665--70.
Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of
3 large managed-care organizations. Clin Infect Dis 2002;35:370--7.
Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults:
a randomized controlled trial. JAMA 1999;282:137--44.
Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention
of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999;18:899--906.
Salgado CD, Giannetta ET, Hayden FG, Farr BM. Preventing nosocomial influenza by improving the vaccine acceptance rate of clinicians.
Infect Control Hosp Epidemiol 2004;25:923--8.
Saito R, Suzuki H, Oshitani H, Sakai T, Seki N, Tanabe N. The
effectiveness of influenza vaccine against influenza A (H3N2) virus infections
in nursing homes in Niigata, Japan, during the 1998--1999 and 1999--2000 seasons. Infect Control Hosp Epidemiol 2002;23:82--6.
Nguyen-Van-Tam J, Granfield R, Pearson J, Fleming D, Keating N.
Do influenza epidemics affect patterns of sickness absence among
British hospital staff? Infect Control Hosp Epidemiol 1999;20:691--4.
Jones A. The National Nursing Home Survey: 1999 summary. National Center for Health Statistics. Vital Health Stat 2002; 13(152):1--125.
Horman JT, Stetler HC, Israel E, Sorley D, Schipper MT, Joseph JM. An outbreak of influenza A in a nursing home. Am J Public
Meiklejohn G, Hall H. Unusual outbreak of influenza A in a Wyoming nursing home. J Am Geriatr Soc 1987;35:742--6.
Goodman RA, Orenstein WA, Munro TF, Smith SC, Sikes RK. Impact of influenza A in a nursing home. JAMA 1982;247:1451--3.
Mixeu MA, Vespa GN, Forleo-Neto E, Toniolo-Neto J, Alves PM. Impact of influenza vaccination on civilian aircrew illness and absenteeism.
Aviat Space Environ Med 2002;73:876--80.
Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the
results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003;21:2207--17.
Nichol KL, Mendelman P. Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative
and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses. Virus Res 2004;103:3--8.
Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001;161:749--59.
US Department of Health and Human Services. Healthy people 2010 (conference ed, in 2 vols). Washington, DC: US Department of Health
and Human Services; 2000. Available at
Bryant KA, Stover B, Cain L, Levine GL, Siegel J, Jarvis WR. Improving influenza immunization rates among healthcare workers caring for
high-risk pediatric patients. Infect Control Hosp Epidemiol 2004;25:912--7.
Ikeda RM, Drabkin PD. Influenza A outbreaks in nursing homes [Comment]. J Am Geriatr Soc 1992;40:1288.
Odelin MF, Pozzetto B, Aymard M, Defayolle M, Jolly-Million J. Role of influenza vaccination in the elderly during an epidemic of A/H1N1
virus in 1988--1989: clinical and serological data. Gerontology 1993;39:109--16.
Sartor C, Tissot-Dupont H, Zandotti C, Martin F, Roques P, Drancourt M. Use of a mobile cart influenza program for vaccination of
hospital employees. Infect Control Hosp Epidemiol 2004;25:918--22.
Russell DW, Cameron DJ, Lockey RF, Behnke RH, Sinnott JT, Ganguly R. Influenza vaccination acceptance among health care
professionals. Vaccine 1991;9:691--2.
Heimberger T, Chang HG, Shaikh M, Crotty L, Morse D, Birkhead G. Knowledge and attitudes of healthcare workers about influenza: why
are they not getting vaccinated? Infect Control Hosp Epidemiol 1995;16:412--5.
Ong AK, Srimanunthiphol J, Frankel RI. Influenza vaccination status of healthcare workers and the extent of their domestic contact
with individuals at high risk for influenza-related complications. Infect Control Hosp Epidemiol 2000;21:735--7.
Goldstein AO, Kincade JE, Gamble G, Bearman RS. Policies and practices for improving influenza immunization rates among healthcare
workers. Infect Control Hosp Epidemiol 2004;25:908--11.
Begue RE, Gee SQ. Improving influenza immunization among healthcare workers. Infect Control Hosp Epidemiol 1998;19:518--20.
LaVela SL, Smith B, Weaver FM, Legro MW, Goldstein B, Nichol K. Attitudes and practices regarding influenza vaccination among healthcare
workers providing services to individuals with spinal cord injuries and disorders. Infect Control Hosp Epidemiol 2004;25:933--40.
Harbarth S, Siegrist CA, Schira JC, Wunderli W, Pittet D. Influenza immunization: improving compliance of healthcare workers. Infect
Control Hosp Epidemiol 1998;19:337--42.
Weingarten S, Riedinger M, Bolton LB, Miles P, Ault M. Barriers to influenza vaccine acceptance. A survey of physicians and nurses. Am J
Infect Control 1989;17:202--7.
Nichol KL, Hauge M. Influenza vaccination of healthcare workers. Infect Control Hosp Epidemiol 1997;18:189--94.
Watanakunakorn C, Ellis G, Gemmel D. Attitude of healthcare personnel regarding influenza immunization. Infect Control Hosp
Briss PA, Rodewald LE, Hinman AR, et al. Reviews of evidence regarding interventions to improve vaccination coverage in children,
adolescents, and adults. The Task Force on Community Preventive Services. Am J Prev Med 2000;18(1 Suppl):97--140.
Poland GA, Tosh P, Jacobson RM. Requiring influenza vaccination for health care workers: seven truths we must accept. Vaccine 2005;23:2251--5.
Martinello RA, Jones L, Topal JE. Correlation between healthcare workers' knowledge of influenza vaccine and vaccine receipt. Infect
Control Hosp Epidemiol 2003;24:845--7.
Nafziger DA, Herwaldt LA. Attitudes of internal medicine residents regarding influenza vaccination. Infect Control Hosp Epidemiol
Manuel DG, Henry B, Hockin J, Naus M. Health behavior associated with influenza vaccination among healthcare workers in
long-term-care facilities. Infect Control Hosp Epidemiol 2002;23:609--14.
McArthur MA, Simor AE, Campbell B, McGeer A. Influenza vaccination in long-term-care facilities. Infect Control Hosp
Ohrt CK, McKinney WP. Achieving compliance with influenza immunization of medical house staff and students. A randomized controlled
trial. JAMA 1992;267:1377--80.
Fedson DS, Houck P, Bratzler D. Hospital-based influenza and pneumococcal vaccination: Sutton's Law applied to prevention. Infect
Control Hosp Epidemiol 2000;21:692--9.
Pachucki CT, Pappas SA, Fuller GF, Krause SL, Lentino JR, Schaaff DM. Influenza A among hospital personnel and patients. Implications
for recognition, prevention, and control. Arch Intern Med 1989;149:77--80.
Adal KA, Flowers RH, Anglim AM, et al. Prevention of nosocomial influenza. Infect Control Hosp Epidemiol 1996;17:641--8.
Steiner M, Vermeulen LC, Mullahy J, Hayney MS. Factors influencing decisions regarding influenza vaccination and treatment: a survey of
healthcare workers. Infect Control Hosp Epidemiol 2002;23:625--7.
Shannon SC. Community hospitals can increase staff influenza vaccination rates. Am J Public Health 1993;83:1174--5.
McKibben L, Horan TC, Tokars JI, et al. Guidance on public reporting of healthcare-associated infections: recommendations of the
Healthcare Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 2005;26:580--7.
Agerton TB, Mahoney FJ, Polish LB, Shapiro CN. Impact of the bloodborne pathogens standard on vaccination of healthcare workers
with hepatitis B vaccine. Infect Control Hosp Epidemiol 1995; 16:287--91.
US Department of Labor, Occupational Safety and Health Administration. 2a CFR Part 1910.1030. Occupational exposure to
bloodborne pathogens: final rule. Federal Register 1991;56:64004-182.
Stewart A, Cox M, Rosenbaum S. The epidemiology of U.S. immunization law: immunization requirements for staff and residents of
long-term care facilities under state laws/regulations. Washington, DC: George Washington University School of Public Health and Health Services;
2005. Available at
Cate TR, Couch RB, Parker D, Baxter B. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza
virus vaccines---1978. Rev Infect Dis 1983;5:737--47.
Kunzel W, Glathe H, Engelmann H, Van Hoecke C. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine
in subjects previously vaccinated or vaccinated for the first time. Vaccine 1996;14:1108--10.
Poland GA, Borrud A, Jacobson RM, et al. Determination of deltoid fat pad thickness. Implications for needle length in adult
immunization. JAMA 1997;277:1709--11.
Riddiough MA, Sisk JE, Bell JC. Influenza vaccination. JAMA 1983;249:3189--95.
King JC Jr, Lagos R, Bernstein DI, et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza
vaccine administered intranasally as drops or spray to healthy children. J Infect Dis 1998;177:1394--7.
Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent,
intranasal influenza virus vaccine. J Infect Dis 2000;181:1133--7.
Boyce TG, Gruber WC, Coleman-Dockery SD, et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine
in children. Vaccine 1999;18:82--8.
Zangwill KM, Droge J, Mendelman P, et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three
lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis J 2001;20:740--6.
Bernstein DI, Yan L, Treanor J, Mendelman PM, Belshe R. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent,
intranasal influenza vaccines on antibody responses in children. Pediatr Infect Dis J 2003;22:28--34.
Nolan T, Lee MS, Cordova JM, et al. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two
manufacturing facilities. Vaccine 2003;21:1224--31.
Vesikari T. Randomized, double-blind, placebo-controlled trial of the safety and transmissibility and phenotypic stability of a live, attenuated,
cold-adapted influenza virus vaccine (CAIV-T) in children attending day care [Abstract G-450]. Presented at the 41st Annual Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Chicago, Illinois, December 16--19, 2001.
Talbot TR, Crocker DD, Peters J, et al. Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults.
Infect Control Hosp Epidemiol 2005;26:494--500.
Ali T, Scott N, Kallas W, et al. Detection of influenza antigen with rapid antibody-based tests after intranasal influenza vaccination (FluMist).
Clin Infect Dis 2004;38:760--2.
Freeman DW, Barno A. Deaths from Asian influenza associated with pregnancy. Am J Obstet Gynecol 1959;78:1172--5.
Widelock D, Csizmas L, Klein S. Influenza, pregnancy, and fetal outcome. Public Health Rep 1963;78:1--11.
Harris JW. Influenza occurring in pregnant women: a statistical study of thirteen hundred and fifty cases. JAMA 1919;72:978--80.
Irving WL, James DK, Stephenson T, et al. Influenza virus infection in the second and third trimesters of pregnancy: a clinical
and seroepidemiological study. BJOG 2000;107:1282--9.
Kort BA, Cefalo RC, Baker VV. Fatal influenza A pneumonia in pregnancy. Am J Perinatol 1986;3:179--82.
Kirshon B, Faro S, Zurawin RK, Samo TC, Carpenter RJ. Favorable outcome after treatment with amantadine and ribavirin in a
pregnancy complicated by influenza pneumonia. A case report. J Reprod Med 1988;33:399--401.
Schoenbaum SC, Weinstein L. Respiratory infection in pregnancy. Clin Obstet Gynecol 1979;22:293--300.
Shahab SZ, Glezen WP. Influenza viruses. In: Gonik B, ed. Viral diseases in pregnancy. New York, NY: Springer-Verlag; 1994.
Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant
women. Am J Epidemiol 1998;148:1094--102.
Heinonen OP, Shapiro S, Monson RR, Hartz SC, Rosenberg L, Slone D. Immunization during pregnancy against poliomyelitis and influenza
in relation to childhood malignancy. Int J Epidemiol 1973; 2:229--35.
National Foundation for Infectious Diseases. Call to action: influenza immunization among health-care personnel, 2003. Bethesda, MD:
National Foundation for Infectious Diseases; 2003. Available at
Govaert TM, Dinant GJ, Aretz K, Masurel N, Sprenger MJ, Knottnerus JA. Adverse reactions to influenza vaccine in elderly people:
randomised double blind placebo controlled trial. BMJ 1993; 307(6910):988--90.
Margolis KL, Nichol KL, Poland GA, Pluhar RE. Frequency of adverse reactions to influenza vaccine in the elderly. A randomized,
placebo-controlled trial. JAMA 1990;264:1139--41.
Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults. A randomized,
placebo-controlled trial. Arch Intern Med 1996;156:1546--50.
American Lung Association Asthma Clinical Research Centers. The safety of inactivated influenza vaccine in adults and children with asthma.
N Engl J Med 2001;345:1529--36.
Scheifele DW, Bjornson G, Johnston J. Evaluation of adverse events after influenza vaccination in hospital personnel. CMAJ 1990; 142:127--30.
Barry DW, Mayner RE, Hochstein HD, et al. Comparative trial of influenza vaccines. II. Adverse reactions in children and adults. Am J
Bierman CW, Shapiro GG, Pierson WE, Taylor JW, Foy HM, Fox JP. Safety of influenza vaccination in allergic children. J Infect
James JM, Zeiger RS, Lester MR, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 1998;133:624--8.
Murphy KR, Strunk RC. Safe administration of influenza vaccine in asthmatic children hypersensitive to egg proteins. J Pediatr 1985;106:931--3.
Zeiger RS. Current issues with influenza vaccination in egg allergy. J Allergy Clin Immunol 2002;110:834--40.
Aberer W. Vaccination despite thimerosal sensitivity. Contact Dermatitis 1991;24:6--10.
Kirkland LR. Ocular sensitivity to thimerosal: a problem with hepatitis B vaccine? South Med J 1990;83:497--9.
Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza
Immunization Program, United States, 1976--1977. Am J Epidemiol 1979;110:105--23.
Safranek TJ, Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine
influenza vaccine in 1976--1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol 1991;133:940--51.
Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. Guillain-Barré syndrome and the 1978--1979 influenza vaccine. N Engl J
Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain-Barré syndrome in the United States, 1979--1980 and 1980--1981. Lack of
an association with influenza vaccination. JAMA 1982;248:698--700.
Chen R, Kent J, Rhodes PH, et al. Investigation of a possible association between influenza vaccination and Guillain-Barré syndrome in the
United States, 1990--1991 [Abstract 40]. Post Marketing Surveillance 1992;6:5--6.
Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992--1993 and 1993--1994 influenza vaccines. N Engl J
Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992; 326:1130--6.
Prevots DR, Sutter RW. Assessment of Guillain-Barré syndrome mortality and morbidity in the United States: implications for acute flaccid
paralysis surveillance. J Infect Dis 1997;175 (Suppl 1):S151--5.
Barohn RJ, Saperstein DS. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Semin Neurol 1998; 18:49--61.
Jackson LA, Holmes SJ, Mendelman PM, Huggins L, Cho I, Rhorer J. Safety of a trivalent live attenuated intranasal influenza vaccine,
FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 1999;17:1905--9.
King JC Jr, Treanor J, Fast PE, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine,
trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect
Izurieta HS, Haber P, Ball R, et al. Post-licensure surveillance of the first live, cold-adapted influenza vaccine in the U.S.
[Abstract]. Pharmacoepidemiol Drug Saf 2004;13(Suppl):S145.
* In this report, the term HCP refers to all paid and unpaid persons working in health-care settings who have the potential for exposure to infectious
materials, including body substances, contaminated medical supplies and equipment, contaminated environmental surfaces, or contaminated air. HCP might
include (but are not limited to) physicians, nurses, nursing assistants, therapists, technicians, emergency medical service personnel, dental personnel,
pharmacists, laboratory personnel, autopsy personnel, students and trainees, contractual staff not employed by the health-care facility, and persons (e.g., clerical,
dietary, housekeeping, maintenance, and volunteers) not directly involved in patient care but potentially exposed to infectious agents that can be transmitted to
and from HCP. The recommendations in this report apply to HCP in acute care hospitals, nursing homes, skilled nursing facilities, physician's offices, urgent
care centers, and outpatient clinics, and to persons who provide home health care and emergency medical services.
These persons should receive inactivated influenza vaccine.
Healthcare Infection Control Practices Committee
Membership List, June 2005
Chairman: Patrick J. Brennan, MD, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
Executive Secretary: Michele L. Pearson, MD, CDC, Atlanta, Georgia.
Members: Vicki L. Brinsko, Vanderbilt University Medical Center, Nashville, Tennessee; Raymond Y. W. Chinn, MD, Sharp Memorial Hospital,
San Diego, California; E. Patchen Dellinger, MD, University of Washington School of Medicine, Seattle, Washington; Nancy E. Foster, American
Hospital Association, District of Columbia; Steven M. Gordon, MD, Cleveland Clinic Foundation, Cleveland, Ohio; Lizzie J. Harrell, PhD, Duke
University Medical Center, Durham, North Carolina; Carol O'Boyle, PhD, University of Minnesota, Minneapolis, Minnesota; Dennis M. Perrotta, PhD,
Texas Department of Health, Austin, Texas; Harriett M. Pitt, MS, Long Beach Memorial Medical Center, Long Beach, California; Robert J. Sherertz,
MD, Wake Forest University School of Medicine, Wake Forest, North Carolina; Nalini Singh, MD, Children's National Medical Center, District
of Columbia; Kurt B. Stevenson, MD, Qualis Health, Boise, Idaho; Philip W. Smith, MD, University of Nebraska Medical Center, Omaha, Nebraska.
Liaison Representatives: William Baine, MD, Agency for Healthcare Research and Quality, District of Columbia; Joan Blanchard, MSS, Association
of periOperative Registered Nurses, Denver, Colorado; Georgia Dash, MS, Association for Professionals of Infection Control and Epidemiology,
Inc., Philadelphia, Pennsylvania; Sandra L. Fitzler, American Healthcare Association, District of Columbia; David Henderson, MD, National Institutes
of Health, Bethesda, Maryland; Lorine Jay, Health Services Resources Administration, Atlanta, Georgia; Stephen F. Jencks, MD, Center for Medicare
and Medicaid Services, Baltimore, Maryland; Chiu S. Lin, PhD, Food and Drug Administration, Rockville, Maryland; Mark Russi, MD, American
College of Occupational and Environmental Medicine, New Haven, Connecticut; Rachel Stricoff, MPH, Advisory Committee for the Elimination
of Tuberculosis, New York, New York; Michael Tapper, MD, Society for Healthcare Epidemiology of America, Inc., New York, New York; and
Robert Wise, MD, Joint Commisssion on the Accreditation of Healthcare Organizations, Oakbrooke, Illinois.
Advisory Committee on Immunization Practices
Membership List, June 2005
Chairman: Myron J. Levin, MD, Professor of Pediatrics and Medicine, University of Colorado Health Sciences Center, Denver, Colorado.
Executive Secretary: Larry Pickering, MD, National Immunization Program, CDC, Atlanta, Georgia.
Members: Jon S. Abramson, MD, Wake Forest University School of Medicine, Winston-Salem, North Carolina; Ban Mishu Allos, MD,
Vanderbilt University School of Medicine, Nashville, Tennessee; Guthrie S. Birkhead, MD, New York State Department of Health, Albany, New York;
Judith Campbell, MD, Baylor College of Medicine, Houston, Texas; Reginald Finger, MD, Focus on the Family, Colorado Springs, Colorado; Janet
Gildsdorf, MD, University of Michigan, Ann Arbor, Michigan; Tracy Lieu, MD, Harvard Pilgrim Health Care and Harvard Medical School,
Boston, Massachusetts; Edgar Marcuse, MD, Children's Hospital and Regional Medical Center, Seattle, Washington; Julia Morita, MD, Chicago Department
of Health, Chicago, Illinois; Gregory Poland, MD, Mayo Clinic College of Medicine, Rochester, Minnesota; John B. Salamone, National Italian
American Foundation, District of Columbia; Patricia Stinchfield, Children's Hospital and Clinics, St. Paul, Minnesota; John J. Treanor, MD, University
of Rochester School of Medicine and Dentistry, Rochester, New York; Robin Womeodu, MD, University of Tennessee Health Sciences Center,
Ex-Officio Members: James E. Cheek, MD, Indian Health Service, Albuquerque, New Mexico; Stephen Phillips, DO, Department of Defense,
Falls Church, Virginia; Geoffrey S. Evans, MD, Health Resources and Services Administration, Rockville, Maryland; Bruce Gellin, MD, National
Vaccine Program Office, District of Columbia; Linda Murphy, Centers for Medicare and Medicaid Services, Baltimore, Maryland; George T. Curlin,
MD, National Institutes of Health, Bethesda, Maryland; Norman Baylor, MD, Food and Drug Administration, Bethesda, Maryland; Kristin Lee
Nichol, MD, Department of Veterans Affairs, Minneapolis, Minnesota.
Liaison Representatives: American Academy of Family Physicians, Jonathan Temte, MD, Clarence, New York, and Richard Clover, MD,
Louisville, Kentucky; American Academy of Pediatrics, Margaret Rennels, MD, Baltimore, Maryland, and Carol Baker, MD, Houston, Texas;
American Association of Health Plans, Robert Scalettar, MD, North Haven, Connecticut; American College Health Association, James C. Turner,
MD, Charlottesville, Virginia; American College of Obstetricians and Gynecologists, Stanley Gall, MD, Louisville, Kentucky; American College
of Physicians, Kathleen Neuzil, MD, Seattle, Washington; American Medical Association, Litjen Tan, PhD, Chicago, Illinois; American
Pharmacists Association, Stephan L. Foster, PharmD, Memphis, Tennessee; Association of Teachers of Preventive Medicine, W. Paul McKinney, MD,
Louisville, Kentucky; Biotechnology Industry Organization, Clement Lewin, PhD, Cambridge, Massachusetts; Canadian National Advisory Committee
on Immunization, Monica Naus, MD, Vancouver, British Columbia; Healthcare Infection Control Practices Advisory Committee, Steve Gordon,
MD, Cleveland, Ohio; Infectious Diseases Society of America, Samuel L. Katz, MD, Durham, North Carolina, and William Schaffner, MD,
Nashville, Tennessee; London Department of Health, David M. Salisbury, MD, London, United Kingdom; National Association of County and City
Health Officials, Nancy Bennett, MD, Rochester, New York; National Coalition for Adult Immunization, David A. Neumann, PhD, Bethesda,
Maryland; National Immunization Council and Child Health Program, Mexico, Romeo Rodriguez, Mexico City, Mexico; National Medical Association, Dennis
A. Brooks, MD, Baltimore, Maryland; National Vaccine Advisory Committee, Charles Helms, MD, PhD, Iowa City, Iowa; Pharmaceutical Research
and Manufacturers of America, Damian A. Braga, Swiftwater, Pennsylvania, Peter Paradiso, PhD, Collegeville, Pennsylvania; and Society for
Adolescent Medicine, Amy Middleman, MD, Houston, Texas.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to